Skip to content

Tracheostomy Practices in Adult Intensive Care Units: A Multicenter Point-Prevalence Study in Izmir (IZ-TRACH)

Tracheostomy Practices in Adult Intensive Care Units in Izmir, Turkey: A Multicenter Point-Prevalence Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07404592
Acronym
IZ-TRACH
Enrollment
282
Registered
2026-02-11
Start date
2025-09-08
Completion date
2025-10-08
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tracheostomy

Keywords

Tracheostomy, Intensive care unit, Mechanical ventilation, Multidisciplinary decision-making, Point-prevalence study

Brief summary

The primary objective of this study was to determine the point-prevalence of tracheostomy in adult intensive care units (ICUs) in Izmir and to characterize the documented reasons for postponement of tracheostomy, with attention to family-related deferral. Secondary objectives included tracheostomy indications, techniques, complications, timing, the relationship between illness severity (APACHE II) and mortality, and short-term outcomes. This multicenter, descriptive point-prevalence study was conducted across eleven adult ICUs in six hospitals on September 8, 2025. Of 282 adult patients present on the index day, 46 had a tracheostomy and formed the analytic subgroup. The study aimed to provide observational data on how tracheostomy is managed in a real-world clinical setting, focusing on the decision-making process and clinical characteristics associated with patient mortality.

Detailed description

This investigation was designed as a multicentre, descriptive point-prevalence study. On the specified prevalence day, all patients aged ≥18 present on the prevalence day were screened; those with an established tracheostomy formed the analytic subgroup. The data collection process involved: * Documentation of ICU structural characteristics across eleven adult ICUs in six hospitals, including bed capacity and annual tracheostomy volumes. * Evaluation of the interval from endotracheal intubation to tracheostomy and identification of documented reasons for any delay. * Assessment of the association between APACHE II score and 30-day in-hospital mortality. * A 30-day follow-up to assess mortality outcomes and causes of death.

Interventions

PROCEDURETracheostomy

The application of surgical or percutaneous dilatational tracheostomy (Griggs guidewire dilating forceps or Ciaglia single-dilator techniques) for indications such as prolonged mechanical ventilation

Sponsors

Izmir City Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years and older * Present in a participating adult ICU on the point-prevalence day

Exclusion criteria

* Patients younger than 18 years

Design outcomes

Primary

MeasureTime frameDescription
30-day in-hospital mortality from the index dateUp to 30 days after the index dayThe proportion of patients who died within 30 days of the index (point-prevalence) date. Because tracheostomies were prevalent (established before the survey), this is a point-prevalence snapshot rather than a procedure-anchored rate.
Point-prevalence of tracheostomy and documented reasons for postponementDay 1The proportion of adult ICU patients with a tracheostomy on the index day, and the distribution of documented reasons for postponement of tracheostomy (including family-related deferral).

Secondary

MeasureTime frameDescription
Intubation-to-tracheostomy interval (days)From endotracheal intubation to tracheostomy, assessed through Day 1Median days from endotracheal intubation to tracheostomy
Distribution of tracheostomy technique (surgical vs percutaneous)Day 1Proportion of surgical versus percutaneous tracheostomies.
Early and late complication rates by techniqueFrom tracheostomy through Day 1Proportion of patients with early and late complications, by technique.
APACHE II score and its discrimination for 30-day mortalityUp to 30 days after the index dayDiscrimination (area under the ROC curve) of the admission APACHE II score for 30-day mortality.
Causes of death among non-survivorsUp to 30 days after the index dayDistribution of causes of death among non-survivors.

Countries

Turkey (Türkiye)

Contacts

STUDY_DIRECTORMurat KAYKAC, M.D.

Izmir City Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026